DOI: 10.17151/biosa.2019.18.2.5
Cómo citar
Moreno Babilonia, C. A., Sánchez Palacio, N., & Cabarcas López, W. F. (2023). Eficacia de las células mesenquimales en el tratamiento de la osteoartritis de rodilla: revisión sistemática. Biosalud, 18(2), 61–80. https://doi.org/10.17151/biosa.2019.18.2.5

Autores/as

César Andrés Moreno Babilonia
Universidad del Sinú
cesar.moreno@unisinu.edu.co
https://orcid.org/0000-0002-4733-6340
Natalia Sánchez Palacio
Universidad de Caldas
natalia.sanchez@ucaldas.edu.co
https://orcid.org/0000-0002-3405-5144
William Fernando Cabarcas López
Fundación Universitaria Visión de las Américas
william.cabarcas@uam.edu.co
https://orcid.org/0000-0002-9533-6791

Resumen

Introducción: Las células madre se consideran uno de los tratamientos con mayor potencial para enfermedades degenerativas. La terapia intraarticular con células madre mesenquimales se usan cada vez más para el tratamiento de la osteoartritis de rodilla con poca evidencia científica para respaldar su uso. Por lo tanto, vale la pena explorar la eficacia, la seguridad y su potencial. Objetivo: Evaluar la calidad de la evidencia sobre la eficacia clínica y radiológica del uso de las células mesenquimales (MSC) intraarticulares en comparación con otros tratamientos por esta misma vía, contra la osteoartritis de rodilla de cualquier etiología para pacientes adultos, reportada entre 2016 y 2021. Materiales y métodos: Se realizó una revisión sistemática de la literatura en diferentes bases de datos de artículos publicados entre el 1 de enero de 2016 y el 22 de agosto de 2021. Estudios que puedan dar respuesta a la pregunta de investigación, siguiendo las directrices de la declaración PRISMA 2020. Resultados: Se obtuvieron 22 ensayos clínicos, que incluyeron 668 pacientes con osteoartritis de rodilla. En todos los estudios se incluyeron pacientes con índice de masa corporal por debajo de 35 kg/m2 y con artrosis Kellgren – Lawrence que oscilaba entre grado I a IV. Conclusiones: En general, el tratamiento con MSC demostró ser seguro y tiene un gran potencial como terapia clínica eficaz para pacientes con artrosis de rodilla, aunque es necesario evaluar su eficacia y seguridad de manera más rigurosa en ensayos con menor riesgo de sesgo.

1. Hunter, DJ, Felson, DT. “Osteoarthritis.” BMJ (Clinical research ed.) 332, no. 7542 (2006): 639-642. https://doi.org/10.1136/bmj.332.7542.639

2. Harrison. Principios de medicina interna 20 ed. México, D.F: McGraw-Hill; 2018.

3. Viteri-Tapia FJ, Muñoz-Suárez DA, Rosales-Pérez GJ, Hernández-Izurieta JP, Jaramillo Villalobos JS, Cortés Naranjo CW. Osteoartrosis. Una revisión de literatura. Rev cubana de Reumatolo. 2019 [citado 31 May 2021]:, 21(2):[aprox. 0 p.]. Doi: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/738

4. Zhao L, Kaye A, Abd-Elsayed A. Stem cells for the treatment of knee osteoarthritis: a comprehensive review. Pain Physician. 2018; 21(3):229-242. Available from: https://pubmed.ncbi.nlm.nih.gov/29871367/

5. Temple-Wong M, Ren S, Quach P, Hansen B, Chen A, Hasegawa A, y col. Hyaluronan concentration and size distribution in human knee synovial fluid: variations with age and cartilage degeneration. Arthritis Res Ther. 2016;18:18. doi: 10.1186/s13075-016-0922-4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721052/

6. Hopman W, Harrison M, Coo H, Friedberg E, Buchanan M, VanDenKerkhof E. Associations between chronic disease, age and physical and mental health status. Chronic Dis Can. 2009; 29(3):108–116. doi: 10.24095/hpcdp.29.3.03. Available from: https://pubmed.ncbi.nlm.nih.gov/19527569/

7. Harris H, Crawford A. Recognizing and managing osteoarthritis. Nursing. 2015; 45(1):36-42. doi: 10.1097/01.NURSE.0000458918.87973.15. Available from: https://pubmed.ncbi.nlm.nih.gov/25479404/

8. Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair. Nat Rev Rheumatol 9:584-594. 2013. Available from: https://pubmed.ncbi.nlm.nih.gov/23881068/

9. Davatchi F, Sadeghi Abdollahi B, Mohyeddin M, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis: 5 years follow-up of three patients. Int J Rheum Dis. 2016; 19:219-225. Available from: https://pubmed.ncbi.nlm.nih.gov/25990685/

10. Kurtz S, Ong K, Lau E, Mowat F, Halpern M.Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Jt Surg Ser A. 2007; 89:780-785. Available from: https://pubmed.ncbi.nlm.nih.gov/17403800/

11. Derar H, Shahinpoor M. Recent patents and designs on hip replacement prostheses. Open Biomed Eng J. 2015 Mar 31; 9:92-102. doi: 10.2174/1874120701509010092. PMID: 25893020; PMCID: PMC4397822. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397822/

12. Srimongkol S. A review of mathematical modeling in total hip replacement. Int Math Forum. 2012; 7:2561–2569. Available from: https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.461.7483&rep=rep1&type=pdf

13. Ding DC, Chang YH, Shyu WC, Lin SZ. Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant. 2015; 24(3):339-47. doi: 10.3727/096368915X686841. Epub 2015 Jan 23. PMID: 25622293.

14. Andia I, Maffulli N. Mesenchymal stromal cell products for intra-articular knee injections for conservative management of osteoarthritis. Ther Adv Musculoskelet Dis. 2021; 13:1759720X21996953. doi:10.1177/1759720X21996953. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897835/

15. Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, Shamseer L, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29; 372:n71. doi: 10.1136/bmj.n71.

16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996 Feb; 17(1):1-12. doi: 10.1016/0197-2456(95)00134-4.

17. Halpern SH, Douglas MJ. Appendix: Jadad Scale for Reporting Randomized Controlled Trials. In: Halpern SH, Douglas MJ, editors. Evidence-based Obstetric Anesthesia. Blackwell Publishing Ltd; 2005. p. 237-238. doi: 10.1002/9780470988343.app. Available from: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9780470988343.app.

18. RevMan 5. Cochrane.org. [citado el 17 de diciembre de 2021]. Doi: https://training.cochrane.org/online-learning/coresoftware-cochrane-reviews/revman/revman-5-download

19. Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant. 2011; 20(1):5-14. doi: 10.3727/096368910X. PMID: 21396235.

20. Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Moltó F, Nuñez-Córdoba JM, Sánchez-Echenique C, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). J Transl Med. 2016; 14(1). doi:http://dx.doi.org/10.1186/s12967-016-0998-2.

21. Lee W-S, Kim HJ, Kim K-I, Kim GB, Jin W. Intra-articular injection of autologous adipose tissuederived mesenchymal stem cells for the treatment of knee osteoarthritis: A phase IIb, randomized, placebo-controlled clinical trial: Autologous MSCs for knee osteoarthritis. Stem Cells Transl Med. 2019; 8(6):504-11. doi: 10.1002/sctm.18-0122.

22. Lu L, Dai C, Zhang Z, Du H, Li S, Ye P, et al. Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, active-controlled, phase IIb clinical trial. Stem Cell Res Ther. 2019; 10(1):143. doi: 10.1186/s13287-019-1248-3.

23. Al-Najar M, Khalil H, Al-Ajlouni J, Al-Antary E, Hamdan M, Rahmeh R, et al. Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study. J Orthop Surg Res. 2017; 12(1). doi: http://dx.doi.org/10.1186/s13018-017-0689-6.

24. Matas J, Orrego M, Amenabar D, Infante C, Tapia-Limonchi R, Cadiz MI, et al. Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: Repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II trial. Stem Cells Transl Med. 2019; 8(3):215-24. doi: http://dx.doi.org/10.1002/sctm.18-0053.

25. Shapiro SA, Kazmerchak SE, Heckman MG, Zubair AC, O’Connor MI. A prospective, single-blind, placebo-controlled trial of bone marrow aspirate concentrate for knee osteoarthritis. Am J Sports Med. 2017; 45(1):82-90. doi: http://dx.doi.org/10.1177/0363546516662455

26. Khalifeh-Soltani S, Forogh B, Ahmadbeigi N, Hadizadeh Kharazi H, Fallahzadeh K, Kashani L, et al. Safety and efficacy of allogenic placental mesenchymal stem cells for treating knee osteoarthritis: a pilot study. Cytotherapy. 2019; 21(1):54-63. doi: 10.1016/j.jcyt.2018.11.003.

27. Tsubosaka M, Matsumoto T, Sobajima S, Matsushita T, Iwaguro H, Kuroda R. The influence of adiposederived stromal vascular fraction cells on the treatment of knee osteoarthritis. BMC Musculoskelet Disord. 2020; 21(1):207. doi: http://dx.doi.org/10.1186/s12891-020-03231-3.

28. Vega A, Martin-Ferrero MA, Del Canto F, Alberca M, Garcia V, Munar A, et al. Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation. 2015; 99(8):1681-90. doi: http://dx.doi.org/10.1097/TP.0000000000000678

29. Wang Y, Jin W, Liu H, Cui Y, Mao Q, Fei Z, et al. Curative effect of human umbilical cord mesenchymal stem cells by intra articular injection for degenerative knee osteoarthritis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2016; 30(12):1472-7. doi: http://dx.doi.org/10.7507/1002-1892.20160305

30. Bastos R, Mathias M, Andrade R, Amaral RJFC, Schott V, Balduino A, et al. Intra-articular injection of culture-expanded mesenchymal stem cells with or without addition of platelet-rich plasma is effective in decreasing pain and symptoms in knee osteoarthritis: a controlled, double-blind clinical trial. Knee Surg Sports Traumatol Arthrosc. 2020; 28(6):1989-99. doi: http://dx.doi.org/10.1007/s00167-019-05732-8

31. Chahal J, Gómez-Aristizábal A, Shestopaloff K, Bhatt S, Chaboureau A, Fazio A, et al. Bone marrow mesenchymal stromal cell treatment in patients with osteoarthritis results in overall improvement in pain and symptoms and reduces synovial inflammation. Stem Cells Transl Med. 2019; 8(8):746-57. doi: http://dx.doi.org/10.1002/sctm.18-0183

32. Emadedin M, Labibzadeh N, Liastani MG, Karimi A, Jaroughi N, Bolurieh T, et al. Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy. 2018; 20(10):1238-46. doi: http://dx.doi.org/10.1016/j.jcyt.2018.08.005

33. Freitag J, Bates D, Wickham J, Shah K, Huguenin L, Tenen A, et al. Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial. Regen Med. 2019; 14(3): 213-30. doi: https://pubmed.ncbi.nlm.nih.gov/30762487/

34. Garay-Mendoza D, Villarreal-Martínez L, Garza-Bedolla A, Pérez-Garza DM, Acosta-Olivo C, Vilchez-Cavazos F, et al. The effect of intra-articular injection of autologous bone marrow stem cells on pain and knee function in patients with osteoarthritis. Int J Rheum Dis. 2018; 21(1):140-7. doi: http://dx.doi.org/10.1111/1756-185X.13161

35. Gupta PK, Chullikana A, Rengasamy M, Shetty N, Pandey V, Agarwal V, et al. Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel®): preclinical and clinical trial in osteoarthritis of the knee joint. Arthritis Res Ther. 2016; 18(1). doi: http://dx.doi.org/10.1186/s13075-016-1195-7

36. Hong Z, Chen J, Zhang S, Zhao C, Bi M, Chen X, et al. Intra-articular injection of autologous adiposederived stromal vascular fractions for knee osteoarthritis: a double-blind randomized self-controlled trial. Int Orthop. 2019; 43(5):1123-34. doi: 10.1007/s00264-018-4099-0.

37. Jo CH, Chai JW, Jeong EC, Oh S, Shin JS, Shim H, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: A 2-year follow-up study. Am J Sports Med. 2017; 45(12):2774-83. doi: 10.1177/0363546517716641.

38. Kazemian G, Rasi AM, Baroutkoub M, Darestani RT. Effect of administration of mesenchymal stem cells on cartilage recovery and knee function in patients with Knee Osteoarthritis. Medical Science. 2020; 24(103):1019-1026.

39. Kuah D, Sivell S, Longworth T, James K, Guermazi A, Cicuttini F, et al. Safety, tolerability and efficacy of intra-articular Progenza in knee osteoarthritis: a randomized double-blind placebo-controlled single ascending dose study. J Transl Med. 2018; 16(1). doi: http://dx.doi.org/10.1186/s12967-018-1420-z

40. Zhao X, Ruan J, Tang H, Li J, Shi Y, Li M, et al. Multi-compositional MRI evaluation of repair cartilage in knee osteoarthritis with treatment of allogeneic human adipose-derived mesenchymal progenitor cells. Stem Cell Res Ther. 2019; 10(1):308. doi: http://dx.doi.org/10.1186/s13287-019-1406-7

41. Garza JR, Campbell RE, Tjoumakaris FP, Freedman KB, Miller LS, Santa Maria D, et al. Clinical efficacy of intra-articular mesenchymal stromal cells for the treatment of knee osteoarthritis: A double-blinded prospective randomized controlled clinical trial. Am J Sports Med. 2020; 48(3):588-98. doi: http://dx.doi.org/10.1177/0363546519899923

42. Weinstein AM, Rome BN, Reichmann WM, Collins JE, Burbine SA, Thornhill TS, Wright J, Katz JN, Losina E. Estimating the burden of total knee replacement in the United States. J Bone Joint Surg Am. 2013 Mar 6; 95(5):385-92. doi: 10.2106/JBJS.L.00206.

43. Thorlund JB, Juhl CB, Roos EM, Lohmander LS. Arthroscopic surgery for degenerative knee: systematic review and meta-analysis of benefits and harms BMJ. 2015; 350:h2747. doi: http://dx.doi.org/10.1136/bmj.h2747

44. Meheux CJ, McCulloch PC, Lintner DM, Varner KE, Harris JD. Efficacy of Intra-articular Platelet-Rich Plasma Injections in Knee Osteoarthritis: A Systematic Review. Arthroscopy. 2016 Mar; 32(3):495-505. doi: 10.1016/j.arthro.2015.08.005.

45. Beyer N, Da Silva L. Mesenchymal stem cells: Isolation in vitro, expansion and characterization. Handb Exp Pharmacol. 2006; (174):249-82. PMID 16370331.

46. Pittenger MF, Mackay AM, Bewck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal cells. Science 1999 Apr; 8(5411):143:7. PMID 10102814.

47. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315-7.

48. Mosna F, Sensebé L, Krampera M. Human bone marrow and adipose tissue mesenchymal stem cells: a user’s guide. Stem Cells Dev 2010; 19 (10): 1449-70.

49. In ‘t Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem cells 2004; 22 (7): 1338-45.

50. Mitrano TI, Grob MS, Carrion F, Nova-Lamperti E, Luz PA, Fierro FS, et al. Culture and characterization of mesenchymal stem cells from human gingival tissue. J Periodontol 2010; 81 (6): 917-25.

51. Chan RW, Schwab KE, Gargett CE. Clonogenicity of human endometrial epithelial and stromal cells. Biol Reprod 2004; 8 (6): 1738-50.

52. In ‘t Anker PS, Noort WA, Scherjon SA, Kleijburg-van der Keur C, Kruisselbrink AB, van Bezooijen RL et al. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica. August 2003; 88(8): 845-52.

53. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. April 2000; 109(1): 235-42.

54. Tornero C, Fernández L. Plasma rico en plaquetas y células madre mesenquimales intrarticulares en artrosis. Rev Soc Esp Dolor 2021; 28(13): 80-84 / DOI: 1020986/resed20213858/2020

55. Lee WS, Kim HJ, Kim KI, Kim GB, Jin W. Intra-Articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Phase IIb, Randomized, PlaceboControlled Clinical Trial. Stem cells translational medicine, June 2019; 8(6): 504-511.

Descargas

Los datos de descargas todavía no están disponibles.
Sistema OJS - Metabiblioteca |